Compare Newmont Corporation (NEM) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newmont Corporation vs Zimmer Biomet Holdings Inc — how do they compare? Newmont Corporation trades at $128.7 (market cap $133.91B), while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $17.97B). The key difference: Newmont Corporation is far larger — about 7.5× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (1.02%). Which is the better fit depends on your goals.
| NEM | ZBH | |
|---|---|---|
Market Cap | $133.91B | $17.97B |
Sector | Basic Materials | Health |
52-Week High | $135.14 | $104.26 |
52-Week Low | $78.32 | $79.58 |
Enterprise Value | $130.50B | $25.04B |
Dividend Yield | 0.82% | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Newmont Corporation (NEM) trades at $127.09, down 0.78% on the day, with strong fundamental performance including a 31.25% net income margin in 2025 and consistent earnings beats. The stock shows bullish technical signals with moving averages supporting upside, while recent news highlights production challenges and institutional accumulation. Revenue growth is robust, projected to reach $25.8 billion in 2026.
Outlook remains positive due to high analyst buy ratings (75.68%) and a $133.29 consensus price target, though risks include operational pressures and gold price volatility. The company's liquidity and debt reduction support shareholder returns, including dividends.
Zimmer Biomet (ZBH) trades at $94.22, down 3.93% on the day, with a bearish technical signal but strong fundamentals including a 69.87% gross margin and three consecutive quarterly earnings beats. Revenue growth is steady, reaching $8.23B in 2025, though net income margin dipped to 8.56%. Recent leadership promotions aim to accelerate commercial transformation, while analyst consensus price target is $104.88, implying 11.3% upside.
The stock presents a value opportunity with a P/E of 22.87 and P/S of 2.17, supported by robust cash flow and dividend payments. Risks include rising debt-to-asset ratio (32.57% in 2025) and competitive pressures. Wall Street sentiment is mixed with 40.48% buy ratings, but technical indicators suggest near-term caution amid bearish moving averages.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
